World first in France: an anti-inflammatory against melanoma

It is in Toulouse, in the very modern Oncopole, that the history of the fight against melanoma is writing a new page. For the past 5 years, doctors have been raising their heads in the face of this skin cancer responsible for 66,000 deaths a year worldwide. Immuno-oncology has upset the prognosis by obtaining remissions: these new treatments change the prognosis in more than 70% of cases. What to do for the 30% in whom the treatment fails? Help the defense system braked by inflammation. The explanation of this simple and brilliant idea whose verification is in Toulouse.

Another world medical first to put to the credit of France. Due to obstinacy and reflection.

There are two researchers like France who count a lot, more motivated by the beauty of reflection and the progress of medicine than by the honors and the money that have developed this very promising essay, in a field where the hope is important: improved outcomes in melanoma, a formidable skin cancer because it too often causes metastases and is expected to explode, especially in women, because of a very close relationship with summer exposure to the sun. A Professor of Dermatology, a specialist in this cancer at the Toulouse hospital that the teams of Why Doctor know well. Professor Nicolas Meyer is in fact already involved in the fight against this cancer and in the numerous victory communiques published since 5 years in the world congresses of oncology where we meet him. Today, it is impossible to imagine a successful team in oncology without associating a biology specialist with the doctor, that is to say, someone who can look at and understand the microscopic fight at play. inside the body between the cancer cell, powerful, super-armed, and the immune forces of our body that must be reorganized and strengthened with drugs. This is why the announcement of this world premiere was made by professors Nicolas Meyer, the clinician, and Professor Bruno Ségui, researcher in biology at the Toulouse Oncopole.

Anti-inflammatories to help patients resistant to new treatments

In France we do not have oil ... but ideas! The formula applies perfectly to this work

One side of the formidable immuno-oncology drugs that have solved 70% of melanoma cancers (and many other cancers because they represent in the world of cancer an unparalleled wave of hope). They "boost" the natural system of defense of the man, the immune system, which is often modified by the cancer itself, by helping the soldiers of the immunity, that is the T cells, to recognize and destroy the cell cancerous.
Very targeted weapons whose first copies date from the beginning of the year 2010. With results never seen in oncology.

70% is an amazing result ... But the others who do not respond? There are several hypotheses. one of the most logical is that of inflammation. In addition to hiding from T lymphocytes, the cancer cell causes a very violent inflammatory reaction when attacked, which has the effect of reducing the response to the anti-cancer drug.

And here comes the second family of exceptional drugs, the anti-inflammatory with the idea of ​​giving, in combination, anti-inflammatories. Not those of everybody who is given in rheumatism or sprains. Not those who have also changed the face of dramatic diseases: inflammatory rheumatism with barbaric names such as rheumatoid arthritis, spondyloarthritis or psoriatic arthritis but which have an admiring resonance in hundreds of thousands of patients for whom life has completely changed.
These are the anti TNF alpha. But beware, their power goes hand in hand with the potential side effects.

It was necessary to have the idea then the authorization to associate the power of these 2 treatments. This is now the case in Toulouse.

See you in two years ...

The release of two French researchers is clear: They announce, the trial in 18 patients of the addition of an anti-TNF alpha to onco immunological treatment. Ambition, but also caution. They make an appointment in two years, to know if the experiment is effective, safe and therefore generalizable to all patients with melanoma.
And probably eventually to all those who will be in immuno-oncological treatment. A considerable challenge and highly anticipated by the quality of reasoning and those who apply it.

Video: "Does your DNA hold the key to preventing adverse drug reactions?" (January 2020).